These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3206151)

  • 21. The treatment of Raynaud's phenomenon.
    Dowd PM
    Br J Dermatol; 1986 May; 114(5):527-33. PubMed ID: 2872912
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of calcium inhibitors excluding cardiac pathology and arterial hypertension].
    Hugues FC; Le Jeunne C
    Therapie; 1989; 44(3):175-81. PubMed ID: 2675379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Esophageal spasm.
    O'Rourke AK; Weinberger PM; Postma GN
    Ear Nose Throat J; 2011 Nov; 90(11):516. PubMed ID: 22109917
    [No Abstract]   [Full Text] [Related]  

  • 24. [The use of calcium antagonists in the treatment of ocular circulation symptoms in the framework of a vasospastic syndrome].
    Gasser P; Flammer J; Mahler F
    Schweiz Med Wochenschr; 1988 Feb; 118(6):201-2. PubMed ID: 3363311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anorexia nervosa and Raynaud's phenomenon: a case report.
    Yucel B; Uzum AK; Ozbey N; Kamali S; Yager J
    Int J Eat Disord; 2007 Dec; 40(8):762-5. PubMed ID: 17607716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of non-cardiac chest pain.
    Achem SR
    Dis Mon; 2008 Sep; 54(9):642-70. PubMed ID: 18725006
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug Treatment of Raynaud's Phenomenon of the Nipple.
    Anderson PO
    Breastfeed Med; 2020 Nov; 15(11):686-688. PubMed ID: 32700966
    [No Abstract]   [Full Text] [Related]  

  • 28. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
    Thompson AE; Pope JE
    Rheumatology (Oxford); 2005 Feb; 44(2):145-50. PubMed ID: 15546967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Improvement of idiopathic Raynaud's phenomenon following local infusion of botulinum toxin].
    Roguedas AM; Misery L
    Ann Dermatol Venereol; 2014; 141(6-7):462-3. PubMed ID: 24951147
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacology of Raynaud's phenomenon].
    Roustit M; Khouri C; Blaise S; Villier C; Carpentier P; Cracowski JL
    Therapie; 2014; 69(2):115-28. PubMed ID: 24926630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical treatment of the Raynaud phenomenon].
    Zicot M
    Phlebologie; 1987; 40(1):47-9. PubMed ID: 3033711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Spasm and Raynaud's phenomenon].
    Fiessinger JN
    Ann Cardiol Angeiol (Paris); 1981; 30(2):91-3. PubMed ID: 7259052
    [No Abstract]   [Full Text] [Related]  

  • 34. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of calcium channel blockers for Raynaud phenomenon.
    Seehusen DA; Huang J
    Am Fam Physician; 2014 Aug; 90(3):143-4. PubMed ID: 25077719
    [No Abstract]   [Full Text] [Related]  

  • 36. Joint hypermobility syndrome and bilateral total occlusion of the ulnar arteries presenting as Raynaud's phenomenon.
    Haberhauer G; Feyertag J; Hanusch-Enserer U; Dunky A
    Clin Exp Rheumatol; 2000; 18(2):270-1. PubMed ID: 10812513
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon.
    La Civita L; Giuggioli D; Del Chicca MG; Longombardo G; Pasero G; Ferri C
    Ann Rheum Dis; 1996 May; 55(5):331-2. PubMed ID: 8660111
    [No Abstract]   [Full Text] [Related]  

  • 38. A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynaud's phenomenon in children treated in a UK paediatric rheumatology centre.
    Gargh K; Baildam EM; Cleary GA; Beresford MW; McCann LJ
    Rheumatology (Oxford); 2010 Jan; 49(1):193-4. PubMed ID: 19797310
    [No Abstract]   [Full Text] [Related]  

  • 39. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (duhuo-tisheng tang with danggui-sini tang): a preliminary study.
    Wu YJ; Luo SF; Yang SH; Chen JY; Yu KH; See LC
    Chang Gung Med J; 2008; 31(5):492-502. PubMed ID: 19097597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin-angiotensin system mediators and Raynaud's phenomenon.
    Wood HM; Ernst ME
    Ann Pharmacother; 2006 Nov; 40(11):1998-2002. PubMed ID: 17003081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.